Singapore, April 15 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National University Hospital
Singapore General Hospital
Tan Tock Seng Hospital
Trial Status: NA
Principal Investigator(s):
Dr Melissa Ooi Gaik Ming
Dr Tertius Tuy
Dr Dheepa Christopher
Published by HT Digital...